Lumexa Imaging (LMRI) Q2 2026 earnings review
Top-Line Rebounds, But Margins Compress Ahead of a Back-Heavy H2
Lumexa Imaging posted a solid 5.1% YoY revenue growth in Q2, recovering from a weather-impacted Q1. The company achieved GAAP profitability, reversing a year-ago net loss, heavily aided by drastically lower interest expenses post-IPO. However, the operational story is less rosy: Adjusted EBITDA flatlined YoY at $56.4M, leading to a 100 basis point margin compression. Management narrowed full-year EBITDA guidance, but maintaining the $238M midpoint implies the company must generate roughly 55% of its annual earnings in the second half of the year, elevating execution risk.
🐂 Bull Case
Consolidated advanced procedures (MRI/CT) grew an accelerating 6.8% YoY. This mix shift is a vital structural tailwind as these procedures reimburse at 3-4x the rate of routine scans.
Interest expense fell 46% YoY to $16.2M in Q2. The transformed balance sheet is freeing up critical cash to fund the company's aggressive 8-10 de novo center annual expansion strategy.
🐻 Bear Case
With H1 Adjusted EBITDA at $107.6M, Lumexa needs ~$130.4M in H2 to hit the midpoint of its narrowed guidance. This back-loaded curve leaves little room for error.
Despite top-line growth, Q2 Adjusted EBITDA was virtually flat YoY ($56.4M vs $56.3M), dragged down by a $5.7M YoY surge in G&A expenses and new public company costs.
⚖️ Verdict: ⚪
Neutral. The volume and revenue recovery from Q1 is encouraging, and the strategic expansion via JVs is on track. However, the margin compression and mathematical reliance on a massive second half make the stock a 'show me' story for the next two quarters.
Key Themes
Margin Compression Contradicts Profitable Growth Narrative
A key tenet of management's narrative is scaling profitable growth, yet Q2 Adjusted EBITDA margin decelerated to 21.4% from 22.4% a year ago. A major culprit is surging General & Administrative expenses, which jumped 30% YoY to $24.4M. This indicates that volume gains and acuity mix shifts are currently being absorbed by rising overhead and the estimated $7M in new public company costs, rather than flowing to the bottom line.
Acuity Mix Shift Toward Advanced Modalities
Advanced modalities remain the primary engine for rate growth. System-wide advanced procedures increased 6.3% YoY, capturing 37.4% of total procedure volume—an acceleration of 111 basis points from Q2 2025. This sustained mix shift toward higher-reimbursing MRI, CT, and PET scans is a critical offset to routine volume sluggishness and forms the backbone of the company's same-store growth algorithm.
Aggressive Footprint Expansion and JV Maturation
The company continues to execute its geographic expansion strategy, announcing four new imaging centers year-to-date and forming a new joint venture with the Hospital for Special Surgery (HSS). This marks their ninth health system partnership. As the 15 de novo centers opened since late 2024 continue to ramp, they are expected to be the primary catalyst for the steep H2 revenue and EBITDA acceleration.
Technology Deployment Easing Throughput Bottlenecks
Operational technology remains a tangible driver of asset utilization. Management is actively rolling out AI-enabled FastScan software, targeted to reach roughly 67% of the MRI fleet by the end of 2026. This technology historically reduces scan times by nearly 60% (from 22 to 8 minutes), opening up roughly 40% more daily capacity per machine without corresponding physical CapEx.
Secular Tailwinds in Outpatient Shift
The macro backdrop remains highly supportive. Lumexa continues to benefit from the structural shift of care away from high-cost Hospital Outpatient Departments (HOPDs) toward lower-cost ambulatory settings. Evolving site-neutrality rules and aging demographics are pushing both patients and payers toward Lumexa's network.
Other KPIs
Reversing sharply downward. Interest expense fell 46% from $30.1M in the prior year quarter. This is the direct result of the Q4 2025 IPO, where $406M in net proceeds was utilized to pay down debt, reducing leverage by two turns. This structurally improves operating cash flow and funds the de novo strategy.
Accelerating significantly. H1 Operating Cash Flow swung to a positive $35.7M compared to negative $11.9M in H1 2025. The combination of lower interest burdens and natural seasonal working capital normalization sets the stage for strong Free Cash Flow generation in the back half of the year.
Accelerating. Up from $8.3M in the prior year, tracking toward management's previously guided ~$50M for the full year 2026. While half of this is temporary legacy M&A amortization, the structural step-up remains a heavy adjustment between GAAP Net Income and Adjusted EBITDA.
Guidance
Stable. The reiterated midpoint of $1.071B implies an approximate 4.7% YoY growth rate over FY25's $1.023B. Given H1 revenue of $516.7M, the guidance requires $554.3M in H2, representing an achievable ~7% sequential half-over-half acceleration driven by normal seasonality and de novo center maturation.
Stable on the midpoint ($238M), but the range was narrowed from $234 - $242M. This midpoint implies roughly 3.4% YoY growth. With $107.6M achieved in H1, the company must generate ~$130.4M in H2. This implies an aggressive ~21% sequential acceleration in H2 vs H1, underscoring high execution risk.
Stable. Reiterated range. Through H1, the company has generated $0.38 in Adjusted EPS, keeping it perfectly on pace to hit the midpoint ($0.74), assuming the projected H2 margin expansion materializes.
Key Questions
Bridge to H2 EBITDA Margin Expansion
Given that Q2 Adjusted EBITDA margins compressed by 100 basis points year-over-year, what specific operational levers (pricing, fixed-cost leverage, or mix) give management confidence in the roughly 21% sequential EBITDA acceleration required in H2 to meet the $238M midpoint?
G&A Expense Run Rate
G&A expenses spiked roughly 30% YoY in Q2. How much of this $24.4M figure is considered steady-state run rate versus temporary integration or one-time public company structuring costs?
JV Unconsolidated Rate Dilution
In Q1, system-wide rate growth trailed consolidated rate growth, implying dilution in the JV segment. Has this dynamic normalized in Q2, and what are the pricing expectations for the unconsolidated book for the remainder of the year?
Cybersecurity Incident Update
In the Q1 call, management disclosed a vendor cybersecurity breach involving Lumexa data. Have there been any material lingering financial or operational impacts, and what investments are being made to harden vendor endpoints?